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Objective:  To evaluate  adverse  reactions  of  the  Bacillus  Calmette–Guérin  (BCG)  Statens  Serum  Institut
(SSI)  (Danish  strain  1331)  used  as intervention  in  a randomized  clinical  trial.
Design: A randomized  clinical  multicenter  trial, The  Danish  Calmette  Study,  randomizing  newborns  to
BCG  or  no  intervention.  Follow-up  until  13 months  of age.
Setting:  Pediatric  and  maternity  wards  at three  Danish  university  hospitals.
Participants:  All  women  planning  to give  birth  at the three  study  sites  (n = 16,521)  during  the  recruitment
period  were  invited  to participate  in  the  study.  Four  thousand  one  hundred  and eighty  four  families
consented  to participate  and  4262  children,  gestational  age  32 weeks  and  above,  were  randomized:  2129
to  BCG  vaccine  and  2133  to  no  vaccine.  None  of  the  participants  withdrew  because  of  adverse  reactions.
Main  outcome  and  measure:  Trial-registered  adverse  reactions  after BCG  vaccination  at  birth.  Follow-up
at  3 and 13  months  by  telephone  interviews  and  clinical  examinations.
Results:  Among  the  2118  BCG-vaccinated  children  we registered  no  cases  of severe  unexpected  adverse
reaction  related  to  BCG  vaccination  and no cases  of  disseminated  BCG  disease.  Two  cases  of regional
lymphadenitis  were  hospitalized  and  thus  classiﬁed  as serious  adverse  reactions  related  to  BCG.  The  most
severe adverse  reactions  were  10  cases  of  suppurative  lymphadenitis.  This  was  nearly  a  ﬁvefold  increase
compared  to what  was  expected  based  on  the summary  of  product  characteristics  of the  vaccine.  All  cases
were  treated  conservatively  and  recovered.  Six of  10 (60%)  families  of children  experiencing  suppurative
lymphadenitis  compared  to 117/2071  (6%)  of those  with  no lymphadenitis  indicated  that the  vaccine had
more adverse  effects  than  exp
Conclusions  and relevance:  BCG
A  higher  incidence  of  suppurat
conservatively  without  sequel
Trial registration:  Trial  registra
© 2016  The  Authors.  Publis
∗ Corresponding author. Tel.: +45 29922892.
E-mail addresses: thomas.nissen@dadlnet.dk, tnnissen@gmail.com (T.N. Nissen), nina
esper.Kjaergaard@regionh.dk (J. Kjærgaard), lmje@dadlnet.dk (L.M. Thøstesen), Gitte.Th
T. Hoffmann), Dorthe.Lisbeth.Jeppesen@regionh.dk (D.L. Jeppesen), Poul.Erik.Kofoed@rs
.aaby@bandim.org (P. Aaby), pryds@dadlnet.dk (O. Pryds), Lone.graff.stensballe@regionh
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.100
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).ected  (p-value  <0.001).
 vaccination  was  associated  with  only  mild  morbidity  and  no  mortality.
ive  lymphadenitis  than  expected  was  observed.  All  children  were treated
ae  or complications.
tion  number  NCT01694108  at www.clinicaltrials.gov
hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
birk@dadlnet.dk (N.M. Birk),
ybo.Pihl@rsyd.dk (G.T. Pihl), thoffmann@dadlnet.dk
yd.dk (P.-E. Kofoed), Gorm.Greisen@regionh.dk (G. Greisen), cb@ssi.dk (C.S. Benn),
.dk (L.G. Stensballe).
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
2 cine 3
1
a
p
v
e
w
m
l
s
h
s
o
v
i
a
L
B
n
T
s
a
r
H
i
d
t
s
i
p
n
I
i
“
s
c
f
a
t
t
[
2
2
t
h
e
o
H
b
c
S
c
d
t
h478 T.N. Nissen et al. / Vac
. Introduction
The Bacillus Calmette–Guérin (BCG) vaccine is the most widely
dministered vaccine in the world, and it remains the primary
rophylaxis against tuberculosis (TB). The protective effect of BCG
accination is well studied, with highest efﬁcacy against active dis-
ase, especially TB meningitis and disseminated TB in children,
hereas there is great variation in the effect of preventing pul-
onary TB [1,2]. BCG is part of the immunization program in most
ow-income countries with a high prevalence of TB and a recent
tudy conﬁrm that it is effective in preventing TB [3]. In most
igh-income countries BCG vaccination was discontinued as a con-
equence of reduced TB prevalence.
The adverse reactions (ARs) of BCG have been described thor-
ughly. The normal local reaction following intradermal BCG
accination is swelling and redness which appears at the site of
njection after a few weeks. This develops into a small pustule or
n ulcer that heals and leaves a small scar after weeks to months.
ocal lymphadenopathy < 1 cm is also part of a normal reaction [4].
CG is considered a safe vaccine and serious ARs are rarely seen [5].
Despite the fact that normal reactions and ARs after BCG vacci-
ation are well described, studies report very different rates [6–8].
his could be due to different vaccination procedures and BCG
trains. Early studies have shown that vaccination technique, dose,
nd preparation of the vaccine are important risk factors for adverse
eactions [9–11], and that BCG strain, change of BCG vaccine, and
IV infection are also signiﬁcant risk factors [12–14]. Differences in
nterpretation of a normal reaction and an AR could also explain the
isparities; the normal local reaction and the ‘adverse’ local reac-
ions represent a continuum of the same pathological process. The
hift from a normal reaction to an AR is often deﬁned by size which
s difﬁcult to assess accurately in a clinical setting.
Recent studies from West Africa have found that BCG, apart from
roviding some protection against TB, may  also have beneﬁcial
on-speciﬁc effects on childhood mortality and morbidity [15,16].
mmunological studies have supported this by showing that BCG
nduces epigenetic changes at the monocyte level which lead to
trained innate immunity” [17]. To investigate these possible non-
peciﬁc effects of BCG vaccination in a high-income country, we
onducted a randomized clinical trial (‘The Danish Calmette Study’)
rom October 2012 to January 2015 in which 4262 Danish children
t birth were randomized to BCG or no intervention [18]. Within
his trial, we evaluated the ARs to BCG when administered in a set-
ing with no routine BCG vaccination and low prevalence of HIV
19].
. Methods
.1. Study design
The Danish Calmette Study is a randomized clinical multicenter
rial investigating the effect of BCG vaccination at birth on child-
ood morbidity in Denmark, where BCG was withdrawn in the
arly 1980s, due to low prevalence of TB. The study was  carried
ut at three Danish university hospitals, Rigshospitalet, Hvidovre
ospital, and Kolding Hospital.
At the three study sites, 4262 children were randomized after
irth to BCG vaccination or no intervention. The primary out-
ome was child morbidity assessed as all-cause hospitalization.
econdary outcomes were obtained by telephone interviews and
linical examinations at the age of 3 and 13 months. The study is
escribed in detail elsewhere [18].
The three study sites were organized differently with respect
o the randomization and vaccination procedure. One study site
ad predominately one midwife vaccinating; at this site most4 (2016) 2477–2482
children were vaccinated more than 24 h after birth. At the other
two sites the task was  split between 11 and 15 midwives, respec-
tively; most children here were vaccinated within the ﬁrst 24 h
of life. All study staff were trained speciﬁcally to administer BCG
vaccination correctly.
2.2. Vaccination procedure
The BCG SSI (Danish strain 1331) was  used in the study. A dose
of 0.05 mL  of the vaccine suspension was  applied intradermally on
the left upper arm. A sterile 1 mL  syringe with a short (25-27 G)
needle was  used for the procedure.
2.3. Data collection
Before giving oral and written consent and again after the vac-
cination, the families were informed about the normal reaction
following a BCG vaccination and were advised to seek more infor-
mation at the Calmette Study homepage if needed [20]. The families
were encouraged to contact the study facility in case of unexpected
reactions or if they felt uneasy about a reaction. To collect informa-
tion regarding study outcomes the families were contacted at 3-
and 13-months by telephone and were subsequently scheduled for
a clinical examination at the study site. During these contacts, infor-
mation on ARs was  collected only when mentioned by the families
and never asked for actively by the study staff.
2.4. Classiﬁcation of adverse events
All potential adverse events were classiﬁed into ﬁve categories
according to standard Good Clinical Practice (GCP) guidelines:
adverse event (AE), adverse reaction (AR), severe adverse event
(SAE), severe adverse reaction (SAR), and suspected unexpected
severe adverse reaction (SUSAR). For the present study, severity
was deﬁned by hospitalization also if the hospitalization was only
brieﬂy and due to anxiousness about an AR, and assessed according
to international guidelines [21]. An AE was  deﬁned as a non-severe
event not causally related to BCG vaccination. An AR was deﬁned as
a non-severe event that was expected after BCG vaccination. This
includes suppurative lymphadenitis when the child was not hospi-
talized. An SAE was  deﬁned as a severe event not causally related
to BCG vaccination. An SAR was deﬁned as a severe event that was
expected after BCG vaccination and led to hospitalization. An SUSAR
was deﬁned as a severe unexpected event with suspected relation
to BCG [22]. This includes disseminated BCG disease. All cases of
SAR and SUSAR were discussed with the data and safety monitor-
ing board (DSMB) and reported to the national health authorities
according to Danish law.
All BCG-vaccine related events were categorized into four cat-
egories: (1) local reactions including abscess at the injection site
and prolonged pustule healing (AR), (2) regional lymphadenitis
(AR; SAR if leading to hospitalization), (3) suppurative lymphadeni-
tis (AR; SAR if leading to hospitalization), and (4) others. The
distinction between regional lymphadenitis and suppurative lym-
phadenitis was  based on the clinical ﬁnding of ﬂuctuant swelling
and/or secretion from a ﬁstula. Most cases of suppurative lym-
phadenitis were conﬁrmed by ultrasound examination [23]. All
cases of suppurative lymphadenitis had preceding regional lym-
phadenitis, but were registered exclusively in the suppurative
lymphadenitis category.2.5. Deaths
All fatalities during follow-up were evaluated for potential rela-
tion to BCG.
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Table  1
Risks of adverse reactions after BCG vaccination according to The Danish Calmette Study and the summary of product characteristics of BCG SSI.
Adverse reaction The Danish Calmette Study SPC of BCG SSI
n/N Risk(95%CI) Risk
Regional lymphadenitis 13/2118 6.1/1000 (3.3/1000–1/100) ≥1/1000–<1/100
4.7/1000 (2.3/1000–8.7/1000) ≥1/10,000–1/1000
S ated children.
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In case  3 it  was  not possible  to  determin e th e exact  m e of  perfo raon  
days (Fig. 1, Table 2). All 10 children were regularly examined and
treated conservatively. Apart from the time of perforation, none of
the children showed signs of pain and were in general unaffected
by their suppurative lymphadenitis.
Table 2
Characteristics of children with suppurative lymphadenitis after BCG vaccination
within The Danish Calmette Study.
N = 10, median (range)
Sex (m)  4
Age at BCG vaccination (days) 0 (0–6)Suppurative lymphadenitis 10/2118 
PC: Summary of product characteristics; n = number of cases; N = number of vaccin
.6. Recording of adverse events
The study had a standard operating procedure (SOP) for the
ecording of adverse events. Evaluation during the study period
evealed some major differences in the recording of adverse events.
ince morbidity is an outcome in itself and registered elsewhere in
he study, some study assistants did not simultaneously register
Es and SAEs in the adverse event log. Furthermore, according to
he SOP, the ARs reported at the families’ initiative during tele-
hone interviews/clinical examinations should be reported in the
-crf, even though classiﬁed as a normal reaction after BCG vaccine;
e experienced some inconsistency in this procedure. Distinction
f an adverse reaction from a normal reaction according to size of
 local abscess or lymphadenitis >1 cm proved difﬁcult to assess
n the telephone and the distinction were inconsistent during data
ollection. These site and interpersonal differences in the interpre-
ation of the SOP imply that we were able to report solid data on the
ore severe ARs only, namely regional lymphadenitis, suppurative
ymphadenitis, SARs, and SUSARs, which all study staff registered
n a similar way.
.7. Treatment of adverse reactions
An SOP for treatment of ARs, SARs, and SUSARs was distributed
y the study to the pediatric departments at the three study sites
o ensure that the three study sites would give a uniform and high
tandard of diagnosis and treatment of possible ARs.
.8. Parents experience with adverse reactions
At the end of the 13-month follow-up interview the parents of
he children in the BCG group were asked if the BCG vaccine had
ore adverse effects than they had anticipated and if they were
atisﬁed with their decision of having their child vaccinated. Level
f agreement was compared between families with and without
egional and suppurative lymphadenitis.
.9. Statistical analysis
Statistical analyses were performed using STATA 13.1 (Statacorp
P, College Station, TX, USA). All risk estimates were assessed rela-
ive to the summary of product characteristics (SPC) of the BCG SSI
nd previously reported studies.
. Results
A total of 4262 children were randomized to BCG or control and
118 children were BCG vaccinated within 7 days of life. Hospital-
zation and morbidity were study outcomes and will be reported
lsewhere (Stensballe et al., submitted; Kjærgaard et al., submit-
ed). Due to the limitations of the non-severe AR data, we  are not
ble to report solid data on all events. Crude numbers of all reg-
stered events are shown as supplementary data, but comparison
ith data from other BCG studies should be done with caution (S
 + 2).
This report focuses on severe adverse reactions categorized
s causally related to BCG vaccination. Two children, one withFig. 1. Time course of 10 cases of suppurative lymphadenitis after BCG vaccination
within The Danish Calmette Study. In case 3 it was not possible to determine the
exact time of perforation
regional lymphadenitis and one with suppurative lymphadeni-
tis, were brieﬂy hospitalized for ultrasonic examination and were
therefore categorized as SARs. They were discharged with conser-
vative management. The severity and time course did not differ
from the other children with regional and suppurative lymphadeni-
tis registered as ARs. No child had disseminated BCG disease. No
cases of SUSARs were seen. The most severe adverse reaction seen
was suppurative lymphadenitis.
3.1. Suppurative lymphadenitis
Suppurative lymphadenitis was  registered for 10 of the
2118 vaccinated children in the study (4.7/1000, [95% CI
2.3/1000–8.7/1000]) (Table 1). All children had lymphadenitis in
the left axilla as their primary symptom. This occurred at a median
age of 87 days, ranging from 25 to 200 days. All cases of suppu-
rative lymphadenitis perforated spontaneously and healed with a
scar in the left axilla. The median time from onset of symptoms
to development of a scar was 198 days, ranging from 63 to 328Age at onset of symptoms (days) 87 (25–200)
Time from onset of symptoms to perforation (days) 71 (26–188)
Time from perforation to healing (days) 153 (25–214)
Time from onset of symptoms to healing (days) 198 (63–328)
2480 T.N. Nissen et al. / Vaccine 34 (2016) 2477–2482
Table 3a
Parental experience of side effects from BCG when asked 13 months after vaccination. BCG vaccinated children within The Danish Calmette Study.
BCG had more side effects than we expected? All Participants with suppurative
lymphadenitis
Participants with regional
lymphadenitis
N = 2071(%)a N = 10(%) p-valueb N = 12(%)c p-valueb
Agree or strongly agree 117(6) 6(60) <0.001 3(25) 0.004
Neither nor, disagree or strongly disagree 1942(94) 4(40) 9(75)
ppura
t
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3
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Pa Only participants not experiencing suppurative or regional lymphadenitis.
b Chi-2 test for comparison with BCG vaccinated participants not experiencing su
c One family with regional lymphadenitis did not answer the questions.
Two different batches were used in the study, with a suppura-
ive lymphadenitis risk of 3/923 (3.3/1000) and 7/1195 (5.9/1000)
accinated, respectively (p-value for same risk = 0.40). The mother
ad been BCG-vaccinated in 20% (2/10) of the children with sup-
urative lymphadenitis. This was comparable to 17.6% for all
CG-vaccinated children.
Non-suppurative regional lymphadenitis was experienced by
3 of the 2118 vaccinated in the study (6.1/1000, [95% CI
.3/1000–1/100]) (Table 1).
.2. Death during follow-up
Four children died during the 13 months follow-up period of
he Danish Calmette Study (0.1%). Three were vaccinated and one
as in the control group. None of the cases were considered to be
elated to the BCG vaccination when evaluated by the local health
uthorities and the DSMB of the Calmette Study (S 3).
.2.1. Case 1: Girl vaccinated on the day of birth
The girl was admitted to the pediatric ward the same day with
ypoglycemia and a heart murmur. Diagnosed with persistent
runcus arteriosus and died 19 days old after surgery for truncus
rteriosus.
.2.2. Case 2: Girl vaccinated two days old
The girl was  admitted 27 days old with apathy and a dis-
ended abdomen. Diagnosed with congenital hepatic mesenchymal
amartoma and died after cardiovascular collapse 29 days old.
.2.3. Case 3: Boy vaccinated one day old
The boy was admitted 78 days old after the child was found
ifeless in bed. Autopsy did not reveal the cause of death and the
hild was diagnosed with sudden infant death syndrome. The DSMB
nd the responsible doctors did not consider BCG vaccination to be
elated to the death..2.4. Case 4: Boy randomized to the control group
The boy was hospitalized two days old with apathy and hypo-
onia. Genetic investigation diagnosed the child with Zellweger
yndrome. The child died 320 days old.
able 3b
arental satisfaction with having their child vaccinated with BCG when asked 13 months
We  are satisﬁed with our decision of
having our child BCG vaccinated?
All Par
lym
N = 2055(%)a N =
Agree or strongly agree 1922(94) 7(7
Neither nor, disagree or strongly
disagree
133(6) 3(3
a Only participants not experiencing suppurative or regional lymphadenitis.
b Chi-square test for comparison with BCG vaccinated participants not experiencing su
c One family with regional lymphadenitis did not answer the questions.tive or regional lymphadenitis.
3.3. Parents experience with adverse reactions
When asked whether they agreed with the statement: “The
BCG vaccine had more adverse effects than we had anticipated”,
6% of the parents agreed or strongly agreed. There was  no signif-
icant difference between parents of boys and girls (5.7% vs. 6.5%,
p-value 0.40). In children with suppurative lymphadenitis or non-
suppurative regional lymphadenitis, 6/10 (60%) and 3/12 (25%),
respectively, indicated to agree or strongly agree. These experi-
ences differed signiﬁcantly from those of parents whose did not
experience suppurative or regional lymphadenitis (p-values <0.001
and 0.004, respectively) (Table 3a).
When asked whether they agreed with the statement: “We  are
satisﬁed with our decision of having our child BCG vaccinated”,
94% of the parents of the overall BCG-vaccinated study popula-
tion agreed or strongly agreed. There was  no signiﬁcant difference
between parents of boys and girls (94% vs. 93%, p-value 0.50). In
children with suppurative lymphadenitis, or regional lymphadeni-
tis, 70% and 83%, respectively, agreed or strongly agreed (p-values
were 0.003 and 0.20 compared with those of parents who  did not
experience suppurative or regional lymphadenitis) (Table 3b).
4. Discussion
In The Danish Calmette Study, we found no SUSARS, and no dis-
seminated BCG disease cases among more than 2000 vaccinated
children. We  found a nearly ﬁvefold higher risk of suppurative
lymphadenitis than anticipated based on the risk of ≥1/10,000 to
1/1000 reported in the SPC for the BCG SSI vaccine whereas the
risk of non-suppurative lymphadenitis was  within the range of
expected events compared to the risk of ≥1/1000 to 1/100 reported
by the SPC [4]. The children with suppurative lymphadenitis were
treated conservatively and all healed without sequelae. Four chil-
dren died during follow-up without a causal relation to the BCG
vaccination. Six percent of families stated that the BCG had more
adverse effects than they had expected.
4.1. StrengthsThe Danish Calmette Study had a followup rate of 98%
(Kjærgaard et al., submitted) and all the study participants lived
in the catchment area for the hospitals hosting the study sites.
 after vaccination. BCG vaccinated children within The Danish Calmette Study.
ticipants with suppurative
phadenitis
Participants with regional
lymphadenitis
 10(%) p-valueb N = 12(%)c p-valueb
0) 0.003 10(83) 0.2
0) 2(17)
ppurative or regional lymphadenitis.
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hus, we are fairly conﬁdent that the reported risk of suppurative
ymphadenitis is accurate.
.2. Limitations
The limitations of this study are the diverse reporting and
ecording of less severe ARs leaving no robust estimates for over-
ll risk of ARs. As this study only relies on parental reporting of
dverse effects there is a risk of underreporting of adverse reactions
hat a focused clinical examination would have revealed. There is
 potential risk that some of the participants withdrew from the
tudy before the occurrence of an adverse reaction. As only 2% were
ost to follow-up and all the study participants lived in the catch-
ent area for the hospitals hosting the study sites we believe that
he risk of bias to the outcome is low.
.3. Comparison with other studies
We  found the risk of suppurative lymphadenitis to be almost
ve times higher than expected. Previous studies have reported
n increase in the incidence of ARs when changing BCG vaccine
train and several studies report such changes when shifting to the
CG SSI strain 1331 [6,24–26]. In many cases, change of vaccine
train also leads to change in dose or techniques, which are both
mportant factors in the development of ARs [13,27]. Other stud-
es report batch variation within the same strain of BCG. This was
escribed in Singapore. A batch-related issue led to a 3–4 fold rise
n the incidence of suppurative lymphadenitis but then returned to
sual incidences. The spike of suppurative lymphadenitis was  most
ikely due to manufacturing issues [28]. We found no signiﬁcant
ifference between the two batches used in our study.
It could be speculated that the increased risk of suppurative
ymphadenitis observed in the present study was because most
others were not BCG vaccinated themselves [29–32]. However,
he prevalence of maternal BCG vaccination in children with suppu-
ative lymphadenitis (2/10 children had BCG vaccinated mothers)
as comparable with that in the rest of the study population (17%).
All children with suppurative lymphadenitis were examined at
he pediatric department and followed as outpatients in collabora-
ion with the principle investigator of The Danish Calmette Study.
one of the children received medical or surgical treatment and
ll lesions healed with no other sequelae than a scar in the left
xilla. This illustrates that though BCG-induced suppurative lym-
hadenitis often is prolonged, it is benign and well-responsive to
onservative treatment [33–35].
No disseminated BCG-infections occurred. In the pre-HIV-
ra, incidences of 1.9/mil (1955–1974) and 4.29/mil (1979–1981)
mong infants <1 year old were reported [36]. Many studies have
hown that BCG vaccination can result in serious complications in
hildren with HIV infection, and other immunosuppressive dis-
ases [8,14,37]. A report of increasing incidence of suppurative
ymphadenitis in Saudi Arabia [38] lead to concern about the use
f BCG in a setting with a 20 times higher incidence of severe com-
ined immunodeﬁciency (SCID) than most European countries[39].
owever, in a Danish setting with low incidence of HIV and of pri-
ary immunodeﬁciency disorders, the risk of severe complication
eems negligible, when care is taken to avoid vaccinating immuno-
ompromised patients by awaiting HIV status in children of HIV
nfected mothers.
In this study we were unable to report an overall AR rate;
e did however ﬁnd that only 6% of the parents experienced the
dverse effects to exceed what they had expected. Prior studies
f the BCG-vaccine revealed varying rates of ARs: A South African
tudy, evaluating BCG SSI strain 1331, reported an overall AR rate
f 3.1/100, whereas an Australian study found an overall AR rate of
/100 [40,41]. In France, an overall incidence of 18/100 in a study4 (2016) 2477–2482 2481
using active case ﬁnding at 4 and 12 months after vaccination were
reported [7]. Active case ﬁnding may  explain the high incidence
with an overreporting of what would have been considered nor-
mal  reactions in other studies with passive case ﬁnding like ours.
Clear deﬁnitions of how to report and register ARs are important,
especially when comparing studies.
A previous study reported different risk rates between boys and
girls with a higher incidence in girls. This could represent a sex
differential adverse effect of the BCG vaccine [41]. It could on the
other hand also represent an over-reporting of local reactions by
parents of girls, as other studies among schoolchildren have shown
that girls are more worried about scar development than boys,
which most likely would be reﬂected in the parents’ threshold for
reporting a local reaction [42]. In our study, parents of girls did not
experience more adverse effects than they expected compared to
parents of boys.
4.4. Perspectives
Clear deﬁnitions of how to report and register ARs are important.
Developing standard information for recipients of BCG, describing
the normal reaction to BCG, and classifying ARs as reactions that
lead to a health care contact could be a possibility. With the emerg-
ing focus on NSEs by WHO, more clinical trials on BCG could be
expected. If BCG is reintroduced in a high-income setting with low
prevalence of TB and HIV this paper adds to the ﬁeld that: (1) BCG
is safe with only well described adverse effects, (2) suppurative
lymphadenitis should be expected to be more common than stated
in the SPC, and (3) treatment of suppurative lymphadenitis can be
handled conservatively.
5. Conclusion
We found higher incidence rate of suppurative lymphadenitis
than reported elsewhere. All children were treated conservatively
and healed without sequelae. This suggests that long-time treat-
ment with antibiotics and/or surgery can be avoided.
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